CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
8.80
+0.33 (3.90%)
Jul 2, 2026, 11:37 AM EDT - Market open
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
The company was incorporated in 2006 and is based in Parsippany, New Jersey.
CorMedix Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Mar 25, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 191 |
| CEO | Joseph Todisco |
Contact Details
Address: 389 Interpace Pkwy, Suite 450 Parsippany, New Jersey 07054 United States | |
| Phone | 908 517 9500 |
| Website | cormedix.com |
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco MBA | Chief Executive Officer and Chairman of the Board of Directors |
| Elizabeth Masson-Hurlburt B.A. | Executive Vice President, Chief Operating Officer and Chief Integration Officer |
| Kaufman Beth Zelnick Esq. | EVice President, Chief Legal and Compliance Officer and Corporate Secretary |
| Susan Blum | Executive Vice President and Chief Financial Officer |
| Beth Steinbrenner | SVice President and Chief Human Resource Officer |
| Dr. Matthew T. David M.D. | Executive Vice President and Chief Business Officer |
| Donna Ucci | Senior Vice President and Head of Global Quality |
| Dr. Tushar Mukherjee | Senior Vice President and Head of Technical Operations |
| Michael Seckler | Executive Vice President and Chief Commercial Officer |
| Dr. Peter Sullivan BCOP, Pharm.D. | Senior Vice President of Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2026 | 8-K | Current Report |
| Jun 25, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 12, 2026 | SCHEDULE 13G/A | Filing |
| Jun 12, 2026 | SCHEDULE 13G/A | Filing |
| Jun 8, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |